Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Robert Davis; Chairman of the Board, President, Chief Executive Officer; Merck & Co Inc Caroline Litchfield; Chief Financial Officer, Executive Vice President; Merck & Co Inc Dean Li; Executive ...

We recently published a list of 15 Best Dividend Stocks To Buy and Hold. In this article, we are going to take a look at ...

2025 EPS Guidance: $8.88 to $9.03. Merck & Co Inc (NYSE:MRK) achieved strong growth in 2024, driven by demand for its innovative portfolio, including KEYTRUDA and the successful launch of WINREVAIR.

Robert Davis; Chairman of the Board, President, Chief Executive Officer; Merck & Co Inc Caroline Litchfield; Chief Financial Officer, Executive Vice President; Merck & Co Inc Dean Li; Executive Vice ...

In a report released yesterday, Umer Raffat from Evercore ISI maintained a Buy rating on Merck & Company (MRK – Research Report). The ...

Financial writer advises caution on investing in Merck & Co., Inc. due to negative sentiment and potential price declines. Click for more on MRK Q4 earnings.

Bernstein analyst Courtney Breen maintained a Hold rating on Merck & Company (MRK – Research Report) yesterday and set a price target of $110.00. The company’s shares closed yesterday at $89.67.

On Tuesday, Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of ...

Major stock indexes closed higher on Friday, driven by corporate earnings reports from tech firms like Alphabet and Amazon.

Merck, with a 76.59% gross margin and $63.17 billion in revenue, continues expanding its global vaccine reach. Moreover, Merck announced a $0.81 quarterly dividend and a $10 billion stock buyback ...